Size dynamics of macroprolactinomas during dopamine-agonist therapy

Prolactinomas account for approximately 40% of all pituitaryadenomas. Medical therapy with dopamine agonistsis highly effective in the majority of cases and representsthe mainstay of therapy. This data provides analysis of the efficacy of this treatment according to the size, localization, age, sex and prolactin level. We analyzed the results of treatment of 176 patients (109 male and 67 female with mean age 34 years) with mean follow-up period 6 month. Tumor size in 52% of patients was more than 36mm. Prolactin level was 2333 - 2218283 mU/l (median 37735). We found that the faster tumor shrinkage was during first 3 month of treatment and we didn't saw any positive dynamic after 12 month. The better results could be taken in treatment of young patients (300000mU/l.